Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Immunotherapy and … nothing else? Studies test a potential paradigm shift in treatment for some people with early stage cancers.
Imjudo plus Imfinzi improved overall survival compared with standard targeted therapy for hepatocellular carcinoma.
The approach appears to benefit people with advanced forms of the disease but whose cancer can still be treated with surgery.
Limiting blood flow to the hands during chemotherapy administration may reduce this common side effect.
Patients treated with tumor-infiltrating lymphocytes saw a 50% reduction in disease progression or death.
Treatment-experienced people who received the antibody-drug conjugate lived three months longer than those who got more chemotherapy.
The Phase III FRESCO-2 trial showed an improvement in progression-free survival.
New tests can detect a common signal across more than 50 types of cancer from tumor DNA in blood.
Patients who added Cabometyx to Opdivo and Yervoy had a 27% lower risk of disease progression or death.
Starting Keytruda before surgery improves the outlook for patients with Stage III-IV melanoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.